Piper Sandler Keeps Their Buy Rating on Amgen (AMGN)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...
Amgen price target raised to $329 from $310 at Piper Sandler
Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...
News Medical2d
Distinct myeloid-derived suppressor cell populations fuel aggressive brain tumor growth
A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...